Pharmacological properties of 2,3-dihydro-9H-isoxazolo [3,2-b] quinazolin-9-one (W-2429. Part 1: Analgesic, antipyretic and antiedema activity.
D000284:Administration, Oral; D000701:Analgesics, Opioid / Q000494:pharmacology; D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal; D001169:Arthritis, Experimental / Q000503:physiopathology; D001241:Aspirin / Q000494:pharmacology; D001831:Body Temperature / Q000187:drug effects; D011431:Dextropropoxyphene / Q000494:pharmacology; D004347:Drug Interactions; D004361:Drug Tolerance; D004487:Edema / Q000503:physiopathology*; D005334:Fever / Q000503:physiopathology; D006801:Humans; D007275:Injections, Intravenous; D007555:Isoxazoles / Q000008:administration & dosage / Q000494:pharmacology* / Q000633:toxicity; D007928:Lethal Dose 50; D008297:Male; D051379:Mice; D009292:Narcotic Antagonists / Q000494:pharmacology; D010080:Oxazoles / Q000494:pharmacology*; D011799:Quinazolines / Q000008:administration & dosage / Q000494:pharmacology* / Q000633:toxicity; D051381:Rats; D019966:Substance-Related Disorders; D013997:Time Factors
D000701:Analgesics, Opioid; D000894:Anti-Inflammatory Agents, Non-Steroidal; D007555:Isoxazoles; D009292:Narcotic Antagonists; D010080:Oxazoles; D011799:Quinazolines; D001241:Aspirin; D011431:Dextropropoxyphene